CompletedEarly Phase 1NCT06251739

Repurposing Ivermectin for PKDL Treatment

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Principal Investigator
Dinesh Mondal, MBBS,MD,PhD
International Centre for Diarrhoeal Disease Research, Bangladesh
Intervention
Ivermectin 6 Mg Oral Tablet(drug)
Enrollment
30 target
Eligibility
18-70 years · All sexes
Timeline
2023 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06251739 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials